Clearmind Medicine Inc.
Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.
CMND | NDAQ
Overview
Corporate Details
- ISIN(s):
- CA1850534027
- LEI:
- Country:
- United States of America
- Address:
- 101-1220 WEST 6TH AVENUE, VANCOUVER, BRITISH COLUMBIA
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical company focused on the discovery and development of novel psychedelic-derived therapeutics. The company's primary objective is to commercialize regulated medicines to solve widespread, under-served health problems, with a lead program targeting Alcohol Use Disorder (AUD). Its core treatment candidate is based on the proprietary psychoactive molecule MEAI (5-Methoxy-2-aminoindane), which is currently undergoing Phase I/IIa clinical trials. Clearmind's research is protected by a robust intellectual property portfolio of 19 patent families, underpinning its mission to provide breakthrough treatments for AUD, binge behaviors, and other mental health conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Clearmind Medicine Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Clearmind Medicine Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Clearmind Medicine Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
